FDA Approves Tirzepatide to Cut CV Risk in Type 2 Diabetes

The FDA approved tirzepatide (Mounjaro; Eli Lilly and Company) to lower the risk of major adverse cardiovascular events (MACE)—cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke—in adults with type 2 diabetes (T2D) who are at high risk for these events, according to a news release from Eli Lilly and Company.¹

For pharmacists, the expanded indication reframes a therapy already familiar for glycemic control and weight reduction as one that now carries a formal cardiovascular claim, sharpening its place in cardiometabolic regimens and the counseling that surrounds them. Tirzepatide is the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist to earn the indication.¹

A Head-to-Head Trial, Not a Placebo Comparison

The approval rests on SURPASS-CVOT (NCT04255433), described by Lilly as the first cardiovascular outcomes trial to test 2 incretin therapies against each other rather than against placebo. The event-driven, randomized, double-blind, phase 3 trial enrolled 13,299 adults with T2D and established atherosclerotic cardiovascular disease across 640 sites in 30 countries. Patients were randomized 1:1 to tirzepatide (15 mg or maximum tolerated dose) or dulaglutide (Trulicity; Eli Lilly and Company) 1.5 mg—a GLP-1 receptor agonist with an established cardiovascular benefit—administered subcutaneously once weekly.^1-3

The design choice matters for how pharmacists read the data. Because dulaglutide already reduces cardiovascular events, noninferiority here is a comparison against active treatment, not against no treatment.²

What the Numbers Show

Over a median follow-up of 210.1 weeks, a primary end point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio [HR], 0.92; 95.3% CI, 0.83-1.01; P = .003 for noninferiority; P = .09 for superiority). Tirzepatide met noninferiority to dulaglutide for MACE; superiority was not established.^1,2

That distinction is the crux of the label. The reported 8% lower relative rate of MACE-3 did not reach statistical significance for superiority, so the indication reflects a demonstrated noninferiority to an agent of proven benefit—not evidence that tirzepatide outperforms it. Pharmacists fielding questions framed around tirzepatide being "better for the heart" can anchor the conversation in what the trial actually established.^1,2

Safety and Counseling Points

The safety profile was generally consistent with tirzepatide's established profile. The most common adverse events were gastrointestinal, generally mild to moderate, and concentrated during dose escalation—reinforcing the value of gradual titration and proactive counseling on nausea, diarrhea, and vomiting when patients start or step up therapy. Labeling continues to carry warnings, including a boxed warning for thyroid C-cell tumors and additional cautions for¹:

• Pancreatitis
• Hypoglycemia, when combined with insulin or sulfonylureas
• Dehydration-related kidney injury

Context from real-world evidence adds nuance to the trial result. A separate claims-based analysis emulating SURPASS-CVOT, published in The BMJ, compared tirzepatide initiators against sitagliptin (Januvia; Merck) as a cardiovascular-neutral proxy and reported a lower 1-year MACE risk with tirzepatide (2.9% vs 4.4%; HR, 0.68; number needed to treat, 70), while cautioning that the observational design cannot rule out residual confounding.

Taken together, the head-to-head trial and the real-world signal frame tirzepatide as a component of comprehensive cardiovascular risk reduction rather than a replacement for established therapies.⁴

REFERENCES

1. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. News release. Eli Lilly and Company. August 28, 2026. Accessed August 28, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular

2. Nicholls SJ, Pavo I, Bhatt DL, et al; SURPASS-CVOT Investigators. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928

3. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClincialTrials.gov Identifier: NCT04255433. Last Updated July 8, 2026. Accessed August 28, 2026. https://clinicaltrials.gov/study/NCT04255433

4. Krüger N, Schneeweiss S, Wang SV. Tirzepatide and the risk of atherosclerotic cardiovascular events: population-based cohort study. BMJ. 2026;394:e100011. doi:10.1136/bmj-2026-100011